Prempro: Potential for a New Arena of Drug Product Liability Litigation?

photo-1 icOendicn July 9, the National Heart, Lung and Blood Institute (NHLBI) announced that it was prematurely ending the Women's Health Initiative (WHI) study designed to assess the risks and benefits of estrogen plus progestin therapy for long-term use. The decision sent millions of women who were using the drug or contemplating hormone replacement therapy clamoring for answers. The data revealed that women participating in the estrogen plus progestin group had an increased risk of breast cancer, heart attack, stroke and venous thrombosis compared to those taking a placebo. Immediately after the results were released, scores of …